Outsource Your Phase I/IIa Project to a CRO Operating with a Flexible Approach.
Whether your project is standard or complex, our Early Phase Business Unit (Phase I/IIa) has a dedicated, streamlined approach that helps ensure we complete your study on schedule and on budget. Our goal is to exceed your expectations. Each and every time.
Consider the advantages:
Comprehensive, Diverse Expertise. Our business model is not limited to any particular therapeutic area or study type. That's because we have the right global resources to help you achieve virtually any Early Phase project goal -- a fact that shows our vast experience history.
Early Phase Study Type Expertise:
- Single Ascending Dose (SAD)
- Experimental Medicine
- Drug-Drug Interaction
- Pharmacokinetics (PK)
- Dosing Finding/Ranging
- Food Effect
- Thorough QT Studies (TQTS)
- Multiple Ascending Dose (MAD)
- Proof of Concept
- Bioavailability/Bioequivalence (BA/BE)
- Pharmcodynamics (PD)
- Bridging Studies
- First in Man (FIM)
Early Phase Therapeutic Expertise:
Focused Commitment. You'll see our commitment to Early Phase studies firsthand through our unique processes, professional experts and dedicated Early Phase Business Unit. Because our strategy enables us to effectively handle a wide range of Early Phase studies with a high-quality approach, our client satisfaction rate is high.
Strong Partnerships. Our Early Phase Business Unit has established preferred partnerships with a variety of exceptional Early Phase facilities. In fact, we have Early Phase partners located around the globe. Our Early Phase expertise, combined with the added value of these outside experts, creates a powerful synergy. Whether a complex first-in-man or a simple bioequivalence study, we have the right model to meet your needs. Our Total Vendor Management process decreases the amount of oversight required by your organization, while increasing the certainty of study quality and achieving deliverable timelines.